Effect of some anticancer drugs and combined chemotherapy on renal toxicity

NeuroSignals

Volumn 5, Issue 1, 1996, Pages 51-58

  Skretkowicz J ^a   Sekulska, M ^a   Danilewicz, M ^a   Wagrowska Danilewicz, M ^a   Polakowski, P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CREATININE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG EFFECT; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY TUBULE NECROSIS; MALE; NEPHROTOXICITY; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CREATININE; CYCLOPHOSPHAMIDE; CYSTITIS; FLUOROURACIL; GLOMERULAR FILTRATION RATE; HEMORRHAGE; KIDNEY; MECHLORETHAMINE; METHOTREXATE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0029961717     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000109173     Document Type: Article

References (23)

1. Schilsky RL: Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982;9:75-83.
2. Drzewoski J, Robak T: Clinical Pharmacology of Anti-Cancer Drugs. Warsaw, NAUKA, 1981, pp 29-109.
3. Liliemark J, Peterson C: Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 1991; 21:213-231.
4. Bonnadonna G, Valagussa P: The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988;48:2314-2323.
5. Gheuens E, Slee PHThJ, De Bruijn EA: Bioavailability of cyclophosphamide in the CMF regimen. Ontologie 1990:13:203-206.
6. Orzechowska-Juzwenko K: Cancer Chemotherapy. Warsaw. PZWL, 1990, pp 22-43.
7. Condit PT, Chancs RE, Joel W: Renal toxicity of methotrexate. Cancer 1969;23:126-131.
8. De Fronzo RA, Colvin OM, Braine H, Robertson GL, Davis PJ: Cyclophosphamide and the kidney. Cancer 1974;33:483-491.
9. Robins TJ, Bowen D, Bui QQ, Tran MT: Modulation of high-dose methotrexate toxicity by a non-toxic level of 5-fluorouracil. Toxicology 1986; 41:61-73.
10. Goldberg L: The prediction value of animal toxicity studies carried out on new drugs. J New Drugs 1963;3: 7-11.
11. Levi F, Boughattas V, Blazsek J: Comparative murine chronotoxicity of anticancer agents on related mechanisms. Annu Rev Chrono-pharmacol 1988;4:283-289.
12. De Bruijn EA, Driessen OMJ, Hermans J: The CMF regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil. Int J Cancer 1991;48:67-72.
13. De Bruijn EA, Driessen O, Leeflang P, Van den Bosch N, Von Strijen E, Slee PHTJ, Hermans J: Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in animal model. Cancer Treat Rep 1986;70:1159-1165.
14. De Bruijn EA, Driessen O, Leeflang P, Van Strijen E, Van den Bosch N, Hermans J: Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluoro-uracil in an animal model. Cancer Treat Rep 1987;71:2167-2169.
15. De Bruijn EA, Geng Y, Hermans J, Driessen O: The CMF regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil. Int J Cancer 1990;45:935-939.
16. Borsi JD, Sagen E, Ing C, Moe PJ: Pharmacokinetics and metabolism of methotrexate: An example for the use of clinical pharmacology in pediatric oncology. Pediatr Hcmatol Oncol 1990;7:13-33.
17. Schomagel J, Me Vie J: Theclinical pharamacology of methotrexate. Cancer Treat Rev 1983;10:53-75.
18. Weiss RB, Poster DS: The renal toxicity of cancer chemotherapeutic agents. Cancer Treat Rev 1982;9: 37-56.
19. Crom WR, Glym-Bomhart AM, Rodman JH, Teresi ME, Kavanagh RE, Christensen ML, Relling MV, Evans WE: Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987;12:168-213.
20. Pitman SW, Parker LM, Tattcrsal MAN, Jaffe N, Frei E: Clinical trials of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590) - Toxicologic and therapeutic observations. Cancer Chemother Rep 1975;3:43-49.
21. Wolford ST, Schrocr RA, Gohs FX, Gallo PP, Brodeck M, Falk HB, Ruhren R: Reference range data base for serum chemistry and hematology values in laboratory animals. J Toxicol Environ Health 1986; 18: 161-188.
22. Tam YK, Axelson JE, McErlane B, Kapil RP, Riggs KW, Ongley R, Price JDE: The pharmacokinetics of metoclopramide in rats with experimental renal and hepatic dysfunction. J Pharmacol Exp Ther 1981; 219:141-144.
23. Moore MJ: Clinical pharmacokineties of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.